Thermo Fisher Scientific (TMO) Equity Average (2009 - 2026)

Thermo Fisher Scientific (TMO) has reported Equity Average for 18 consecutive years, with $52.7 billion the latest figure, recorded in Q1 2026.

• Equity Average for Q1 2026 came in at $52.7 billion, up 6.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $52.7 billion (up 6.51% YoY), and the FY2025 annual result was $51.5 billion, up 6.95% from the prior year.
• Equity Average was $52.7 billion for Q1 2026 at Thermo Fisher Scientific, up from $52.2 billion in the prior quarter.
• Over five years, Equity Average peaked at $52.7 billion in Q1 2026 and troughed at $40.9 billion in Q2 2022.
• Average Equity Average over 5 years is $46.5 billion, with a median of $46.1 billion recorded in 2024.
• Year-over-year, Equity Average climbed 17.66% in 2022 and gained 3.29% in 2023.
• Over 5 years, Equity Average stood at $43.8 billion in 2022, then climbed by 5.05% to $46.0 billion in 2023, then gained by 7.01% to $49.3 billion in 2024, then gained by 6.0% to $52.2 billion in 2025, then increased by 0.87% to $52.7 billion in 2026.
• Per Business Quant data, the three most recent Equity Average figures were $52.7 billion in Q1 2026, $52.2 billion in Q4 2025, and $50.8 billion in Q3 2025.